| Ytd | 150.33% | |
| 1y | 1.89% |
| Open | 3.92 | Prev Close | 3.95 | Low | 3.77 | High | 3.95 | Mkt Cap | 236.80M |
| Vol | 461.60K | Avg Vol | 1.40M | EPS | -0.77 | P/E | -5.13 | Forward P/E | -3.49 |
| Beta | 0.95 | Short Ratio | 0.75 | Inst. Own | 42.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.80 | 200-d Avg | 2.87 | 1yr Est | 12.50 |
ELDN News
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-
Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cel
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Tr
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically signif
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have
– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no
IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq:
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to t
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: EL
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart foll
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have been given an average r
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following is
Eledon Pharmaceuticals remains a "Strong Buy" following positive phase 2 BESTOW results for tegoprub
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:
Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerlan
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq:
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: E
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean
During Wednesday's session, 212 companies made new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report